OBIO Orchestra BioMed Holdings Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OBIO

Price (delayed)

$3.98

Market cap

$238.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.97

Enterprise value

$243.59M

?
Relative Growth: Rel. Growth: 67
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 30
Highlights
Orchestra BioMed Holdings's quick ratio has surged by 114% YoY and by 8% QoQ
Orchestra BioMed Holdings's EPS has increased by 46% YoY and by 13% from the previous quarter
The equity has soared by 144% YoY but it has contracted by 23% from the previous quarter
OBIO's net income is up by 18% YoY but it is down by 3.7% QoQ
Orchestra BioMed Holdings's debt has soared by 105% YoY and by 3.7% from the previous quarter
Orchestra BioMed Holdings's revenue has decreased by 2.3% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OM

Key stats

What are the main financial stats of OBIO

OBIO stock price

How has the Orchestra BioMed Holdings stock price performed over time
Intraday
-1.49%
1 week
2.84%
1 month
-1.97%
1 year
23.6%
YTD
-4.1%
QTD
-6.35%

Financial performance

How have Orchestra BioMed Holdings's revenue and profit performed over time
Revenue
$32.72M
Gross profit
$32.55M
Operating income
-$54.96M
Net income
-$54.64M
Gross margin
99.5%
Net margin
-167%
Orchestra BioMed Holdings's net margin has soared by 93% YoY but it has decreased by 6% from the previous quarter
OBIO's operating margin has soared by 93% YoY but it is down by 9% QoQ
The operating income has grown by 20% year-on-year but it has declined by 6% since the previous quarter
OBIO's net income is up by 18% YoY but it is down by 3.7% QoQ

Price vs fundamentals

How does OBIO's price correlate with its fundamentals

Growth

What is Orchestra BioMed Holdings's growth rate over time

Valuation

What is Orchestra BioMed Holdings stock price valuation
P/E
N/A
P/B
5.65
P/S
7.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.44
Orchestra BioMed Holdings's EPS has increased by 46% YoY and by 13% from the previous quarter
The equity has soared by 144% YoY but it has contracted by 23% from the previous quarter
The price to book (P/B) is 94% lower than the last 4 quarters average of 90.4
OBIO's price to sales (P/S) is 94% less than its 5-year quarterly average of 132.3 and 68% less than its last 4 quarters average of 23.7
Orchestra BioMed Holdings's revenue has decreased by 2.3% QoQ

Efficiency

How efficient is Orchestra BioMed Holdings business performance
Orchestra BioMed Holdings's ROS has soared by 93% YoY but it has decreased by 4.2% from the previous quarter
Orchestra BioMed Holdings's return on invested capital has surged by 55% YoY and by 16% QoQ
The company's return on assets rose by 36% YoY and by 8% QoQ
OBIO's ROE is up by 16% year-on-year and by 15% since the previous quarter

Dividends

What is OBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OBIO.

Financial health

How did Orchestra BioMed Holdings financials performed over time
The company's total assets is 103% higher than its total liabilities
Orchestra BioMed Holdings's quick ratio has surged by 114% YoY and by 8% QoQ
OBIO's current ratio has surged by 110% year-on-year and by 9% since the previous quarter
Orchestra BioMed Holdings's debt is 18% less than its equity
The equity has soared by 144% YoY but it has contracted by 23% from the previous quarter
Orchestra BioMed Holdings's debt has soared by 105% YoY and by 3.7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.